Amporin
Basel, CH · 1 known investors
Find your way into Amporin
1,223 people in our graph share verified history with the Amporin team — schools, employers, funds. One of them is your warm intro.
David Phuunlockedknows Kelvin Stott · together at PwC (overlapped)
×7knows the team · via PwC
knows the team · via McKinsey & Company
×2knows the team · via University of Sussex
knows the team · via Merck Serono
Amporin Pharmaceuticals develops small-molecule drugs targeting toxic membrane pores formed by misfolded protein oligomers to treat neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Type 2 diabetes. The company aims to slow or halt disease progression and enable functional recovery in patients with protein misfolding and aggregation disorders.
Founders & leadership
KS
Kelvin StottinCEO and CofounderKelvin Stott brings over 25 years of experience in pharmaceutical R&D strategy, drug discovery and development, portfolio management, and business operations across biotech startups and venture capital. He holds expertise in innovation and performance management, having worked in strategy consulting and led multiple drug development programs.
HS
Hervé SchaffhauserinCSO and CofounderHervé Schaffhauser is a neuropharmacologist with over 20 years of drug development experience spanning target validation, preclinical studies, and Phase 1 clinical trials across pharmaceutical companies and startups. He has contributed to regulatory submissions and led preclinical programs involving small-molecule and large-molecule therapeutics including mRNA and AAV-based approaches.
DU
Daniel UmbrichtinCMO and CofounderHe has expertise in early clinical development, translational neuroscience, electrophysiology, and clinical research methodology, with prior work in schizophrenia and mood disorder research.
Investors · 1
Frequently asked questions
- What does Amporin do?
- Amporin Pharmaceuticals develops small-molecule drugs targeting toxic membrane pores formed by misfolded protein oligomers to treat neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Type 2 diabetes. The company aims to slow or halt disease progression and enable functional recovery in patients with protein misfolding and aggregation disorders.
- Who founded Amporin?
- Amporin was founded by Kelvin Stott, Hervé Schaffhauser, Daniel Umbricht.
- Who are Amporin's investors?
- Amporin's investors include Kickfund.
- Where is Amporin headquartered?
- Amporin is headquartered in Basel, CH.